Ayu Life Sciences, a company of medical devices and cells based in India, announced plans to establish a new advanced manufacturing installation AED33 million ($ 9 million) in Jebel Ali Free Zone (Jafza).
The new installation is announced as your child’s first in the region. The installation of 13,500 square meters will focus on the production of general wound care solutions and surgical treatments, designed to meet the growing global demand for high quality sustainable health products.
India’s help expands worldwide
Dr. Rajan Datt, managing director of Ayu Life Sciences, said the company is excited to announce the new facilities in Jafza, marking an important milestone for it.
“We hope to start this new installation and extend the scope of our flagship products such as Velgraft, Velvert and Velnez to more patients in the Middle East and worldwide,” he said.
Abdulla al Hashmi, director of operations Parks & Zones, DP World GCC, said Jafza’s manufacturing infrastructure and strategic connectivity make it the ideal launch for innovatives such as Ayu Life Sciences.
“This installation reinforces Dubai’s growing role as a global center for medical and advanced medical manufacturing sectors,” he said.
The launch occurs in the middle of an increase in the demand for artificial skin, and the market is projected that it will grow from $ 3.1 billion in 2024 to $ 5.3 billion by 2032.
The installation will be developed in two phases, with phase 1 scheduled at the end of 2025, and the complete completion by 2027.
It will produces ayu life sciences’ flagship products, including velgraft, an artificial skin substitute design for scar-free healing and tissue regeneration, vertart, a natural antimicrobial wound care dressing formulated to acceleration and velnez, and and and and and and and and and and and Thingal, and and Reverate, and and Reverate, and and pre -action, and prescriptions, and and realtes, and and preceptions, and previously, and present, and pressures, and the prices of the patient comfort and post -surgical recovery.
These solutions are backed by a portfolio or 22 global patents and develop using ecological materials and natural components to minimize the environmental impact.
The company currently exports from its installation of Delhi to about 20 markets in North America, Europe, Asia, Australia, Africa and the Middle East.
In addition to the advanced wound care, Ayu’s life sciences, progress is in the field of regenerative medicine.
Clinical trials are underway for a novel therapy that uses cells similar to those of the pancreas to regulate blood sugar for patients with type 1 diabetes, and for Velnererve, a solution for peripheral nerve lesions.
With Jafza and home of more than 800 manufacturing companies from 75 countries, Ayu Life Sciences joins a prosperous ecosystem of global innovatives.
